8 minutes | May 16th 2018

143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

May 16, 2018  Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com  1:25 Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa https://www.prnewswire.com/news-releases/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-epidermolysis-bullosa-300649448.html 3:21 FDA approves first epoetin alfa biosimilar for the treatment of anemia https://www.prnewswire.com/news-releases/fda-approves-first-epoetin-alfa-biosimilar-for-the-treatment-of-anemia-300648734.html https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607703.htm 4:21 Medic Vision: new FDA-cleared MRI image enhancement technology enables reduction of scan time and increased resolution https://www.prnewswire.com/news-releases/medic-vision-new-fda-cleared-mri-image-enhancement-technology-enables-reduction-of-scan-time-and-increased-resolution-682660651.html 5:26 Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis https://www.prnewswire.com/news-releases/novartis-announces-fda-approval-of-gilenya-as-the-first-disease-modifying-therapy-for-pediatric-relapsing-multiple-sclerosis-300647266.html https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607501.htm  Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Play
Like
Play Next
Mark
Played
Share